Press Releases

FDA Acceptance of US Submission of Cellegesic™ (nitroglycerin) 0.4% Ointment - 10/21/2009

ProStrakan Announces Abstral NDA Filing - 10/06/2009

ProStrakan Announces US Submission of Fortigel (testosterone) 2% Gel - 05/12/2009

ProStrakan Announces US Co-Promotion Agreement for Oncology Support Product, Gelclair^® - 05/12/2009

Now available SANCUSO^®, the first and only patch for CINV - 11/04/2008

FDA Approves SANCUSO^®, the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy - 9/15/2008

ProStrakan and Orexo Extend Licensing Agreement for Rapinyl/Abstral to Include North America - 7/31/2008

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men with Type 2 Diabetes and Metabolic Syndrome - 6/17/2008

New Survey Shows Oncology Nurses Urge "Zero Tolerance" Policy to
Prevent Nausea and Vomiting in Patients – 2/19/2008

Board Change – 1/28/2008         

Director/PDMR Shareholding – 1/14/2008          

ProStrakan Reports Further Strong Progress in Preclose Update – 1/8/2008

Grant of Awards and Options – 1/7/2008           

Positive US Phase III Interim Data on Rapinyl™ Released by Endo Pharmaceuticals Inc – 12/17/2007           

Notification of Major Interests in Shares – 12/12/2007           

Peter Allen Takes Up Position as Chairman of ProStrakan – 12/7/2007

ProStrakan Receives Approval for Adcal-D₃ Dissolve™ – 12/3/2007

Financial Calendar 2008 – 11/26/2007         

Peter Allen to Succeed Harry Stratford as Chairman of ProStrakan – 10/30/2007

ProStrakan to Establish US Sales Force Through Strategic Alliance With NovaQuest – 10/22/2007           

Additional Listing – 10/10/2007      

Regulatory Update – 9/28/2007          

ProStrakan and Galapagos Receive Additional Milestone Payment – 9/27/2007

Notification of Major Interests in Shares – 9/21/2007          

Interim Results for the Six Months Ended June 30, 2007 – 9/12/2007           

ProStrakan Announces Commencement of Recruitment in Pivotal US Trials for Fortigel™ (Tostran™) and Cellegesic™ (Rectogesic™) – 8/20/2007           

ProStrakan Announces LG Life Sciences as South Korean Partner for SANCUSO™ – 8/13/2007           

ProStrakan Launches Nordic Sales Joint Venture With Orexo – 8/1/2007